CASP3 and lung carcinoma: Treatment of lung cancer cell lines with pitavastatin or fluvastatin at concentrations between 0.1–100 μM for 72 h led to caspase 3 activation and PARP cleavage as well as typical morphological changes like rounding of the cells and detachment from the surface, indicating apoptosis.